Oppenheimer Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by Oppenheimer from $1,150.00 to $1,000.00 in a research note released on Wednesday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on REGN. Barclays cut their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Evercore ISI dropped their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,092.62.

Regeneron Pharmaceuticals Price Performance

REGN traded up $3.94 on Wednesday, hitting $828.42. 563,585 shares of the stock were exchanged, compared to its average volume of 522,278. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $91.04 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 3.12 and a beta of 0.15. The business has a 50-day moving average of $1,021.70 and a two-hundred day moving average of $1,036.38. Regeneron Pharmaceuticals has a 12 month low of $783.57 and a 12 month high of $1,211.20.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of REGN. Norden Group LLC increased its position in Regeneron Pharmaceuticals by 48.1% during the first quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company’s stock valued at $373,000 after acquiring an additional 126 shares during the last quarter. Quent Capital LLC raised its holdings in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 19 shares during the period. Csenge Advisory Group lifted its position in Regeneron Pharmaceuticals by 12.3% during the first quarter. Csenge Advisory Group now owns 449 shares of the biopharmaceutical company’s stock valued at $432,000 after purchasing an additional 49 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in Regeneron Pharmaceuticals by 33.7% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $1,528,000 after purchasing an additional 400 shares during the period. Finally, AIA Group Ltd increased its position in Regeneron Pharmaceuticals by 45.9% in the first quarter. AIA Group Ltd now owns 6,888 shares of the biopharmaceutical company’s stock worth $6,630,000 after buying an additional 2,166 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.